secwatch.observer — SEC 8-K summary
======================================

Issuer:     Design Therapeutics, Inc. (DSGN)
CIK:        0001807120
Form:       8-K
Filed at:   2021-08-06T23:59:59+00:00
Accession:  0001193125-21-239304
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Design Therapeutics VP Finance Resigns; Controller Appointed Interim Principal Accounting Officer
--------------------------------------------------------------------------------

- Justin Thacker resigned as VP Finance and principal accounting officer effective August 13, 2021.
- Dawn Giangiulio, Controller since April 2020, appointed interim principal accounting officer effective August 13, 2021.
- Giangiulio also serves as Controller of ARS Pharmaceuticals on a part-time basis, resigning September 3, 2021.
- Previously, Giangiulio was Senior Manager R&D Finance at Teva Pharmaceutical Industries from 2015 to 2020.
- Giangiulio is a licensed CPA and began her career at PricewaterhouseCoopers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1807120/000119312521239304/0001193125-21-239304-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1807120/000119312521239304/d203283d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-239304

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer